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In Alzheimer disease (AD) and frontotemporal dementia the
microtubule-associated protein Tau becomes progressively
hyperphosphorylated, eventually forming aggregates. However,
how Tau dysfunction is associated with functional impairment
is only partly understood, especially at early stages when Tau is
mislocalizedbut has not yet formedaggregates. Impaired axonal
transport has been proposed as a potential pathomechanism,
based on cellular Tau models and Tau transgenic mice. We
recently reported K369I mutant Tau transgenic K3 mice with
axonal transport defects that suggested a cargo-selective
impairment of kinesin-driven anterograde transport by Tau.
Here, we show that kinesin motor complex formation is dis-
turbed in the K3 mice. We show that under pathological condi-
tions hyperphosphorylated Tau interacts with c-JunN-terminal
kinase- interacting protein 1 (JIP1), which is associated with the
kinesin motor protein complex. As a result, transport of JIP1
into the axon is impaired, causing JIP1 to accumulate in the cell
body. Becausewe found trapping of JIP1 and apathologicalTau/
JIP1 interaction also inADbrain, thismay have pathomechanis-
tic implications in diseases with a Tau pathology. This is sup-
ported by JIP1 sequestration in the cell body of Tau-transfected
primary neuronal cultures. The pathological Tau/JIP1 interac-
tion requires phosphorylation of Tau, and Tau competes with
the physiological binding of JIP1 to kinesin light chain. Because
JIP1 is involved in regulating cargo binding to kinesin motors,
our findingsmay, at least in part, explain howhyperphosphoryl-
ated Taumediates impaired axonal transport in AD and fronto-
temporal dementia.
The microtubule-associated protein Tau is predominantly
found in the axonal compartment of neurons, where it binds to
microtubules (1). In human brain, six isoforms of Tau are
expressed, due to alternative splicing of exons 2, 3 and 10 (2).
Tau consists of an amino-terminal projection domain followed
by 3 or 4microtubule binding repeats (3R or 4R), due to splicing
of exon 10, and a carboxyl-terminal tail region. In the AD3 and
FTD brain, Tau forms filamentous inclusions (3). They are
found in nerve cell bodies and apical dendrites as neurofibril-
lary tangles (NFTs), in distal dendrites as neuropil threads, and
in the abnormal neurites that are associated with some amyloid
plaques (neuritic plaques) (3). Hyperphosphorylation of Tau is
thought to be an initiating step (4), as it detaches Tau from
microtubules and makes it prone to form aggregates (1, 5).
Whereas inADnomutations have been identified in theMAPT
gene encoding Tau, so far 42 intronic and exonic mutations
have been found in familial forms of FTD (6). Their identifica-
tion assisted in the generation of transgenic mousemodels that
reproduce NFT formation and memory impairment (7).
The models were also instrumental in testing hypotheses
that had been brought forward to link Tau pathology to func-
tional impairment (8–10). In particular, defects in axonal trans-
port have been implicated in neurodegenerative disorders (11,
12). Tau binding to microtubules affects axonal transport (13),
and in cell culture overexpression of Tau was shown to lead to
impaired transport of mitochondria and vesicles (14, 15).
Axonal transport defects have also been reproduced in wild-
type Tau transgenic mice (16) and in K369I mutant Tau K3
mice (17), whereas Tau expression failed to inhibit axonal
transport in other systems (18, 19). This apparent discrepancy
may depend on the type of cargos analyzed and, specifically, the
experimental paradigm, e.g. using phosphorylated (16, 17, 20)
versus non-phosphorylated Tau (18).
To dissect Tau-mediated axonal transport defects at a
molecular level, we used K3 mice that overexpress human Tau
carrying the pathogenic FTD K369I mutation (17). We
observed a pronounced hyperphosphorylation of transgenic
Tau in many brain areas. Clinically, the mice present with an
early onset motor phenotype that is, at least in part, caused by
impairment of axonal transport in neurons of the substantia
nigra. Interestingly, only selected aspects of anterograde axonal
transport were impaired, in particular those of kinesin-I motor
complex-driven vesicles and mitochondria. Our data suggest a
selective impairment of axonal transport rather than a general-
ized, non-selective blockage of microtubules that has been
established in cell culture systems, which fail to phosphorylate
Tau at the high levels that are found in vivo even under physi-
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ological conditions. More importantly, in AD and FTD Tau is
even more phosphorylated, i.e. hyperphosphorylated at physi-
ological sites and de novo at pathological sites, preventing it
from binding to microtubules (1).
Based on our findings of an impaired kinesin-I-driven axonal
transport in the K3 mice, we speculated that hyperphosphoryl-
ated Tau may impair anterograde transport by interfering
directly with components of the kinesin-I motor complex
rather than disrupting the binding of the kinesin heavy chain
(see below) to microtubules. Axonal transport along microtu-
bules is mediated by members of the kinesin superfamily (KIF)
of motor proteins (21–23). The KIFs typically consist of an
ATPase domain that interacts with microtubules and drives
movement and a domain that links to cargos, either directly or
indirectly, as in the case of KIF5, by assembling with the kinesin
light chain (KLC) to form the kinesin-I (KIF5/KLC) motor
complex (24). In addition, increasing evidence suggests that
scaffolding proteins mediate and regulate the binding of cargos
to KIFs (21, 25–27). These include the scaffold protein JNK-
interacting protein (JIP) that is involved in the linkage of cargos
to the kinesin-I motor complex via KLC (25, 28–33).
Here, by using the K3 mouse model, we identified a novel
interaction of Tau and JIP in neurons that causes a trapping of
JNK interacting protein 1 (JIP1) in the cell body of K3mice, cell
culture systems, and humanAD brain.We found that the path-
ological interaction of hyperphosphorylated Tau and JIP1 com-
petes with the physiological binding of JIP1 to KLC.
EXPERIMENTAL PROCEDURES
Mice—The generation of K3 mice expressing K369I mutant
human Tau has been described (17). Animal experiments were
approved by the Animal Ethics Committee of the University of
Sydney, Australia.
Histology and Immunohistochemistry—Ketamine/xylazine
(Troy Laboratories)-anesthetized mice were perfused with 20
ml of cold phosphate-buffered saline followed by 20 ml of 4%
paraformaldehyde (Sigma), and tissue was dissected and post-
fixed overnight at 4 °C. Tissue embedding was done in paraffin
in a Shandon Excelsior processor (Thermo). Human AD and
control tissue was obtained through the Australian Brain Bank
Program as described (10). Immunohistochemistry on 3-m
sections has been described in detail before (34). Primary anti-
bodies to Tau phosphorylated at Thr-231/Ser-235 (AT180
(Pierce)) and to JIP1 (Zymed Laboratories Inc.) were visualized
using the ABC Elite Kit (Vector) or Alexa-labeled secondary
antibodies (Molecular Probes). For subsequent NFT staining,
coverslips were removed after taking fluorescence images fol-
lowed by Gallyas silver staining using a standard protocol (35).
Overlays were made using landmarks.
Western Blotting and Immunoprecipitation—Proteins were
extracted from brain tissues in radioimmunoprecipitation
assay buffer (50 mM Tris, pH 8.0, 150 mM sodium chloride, 1%
Nonidet P-40, 5 mM EDTA, 0.5% sodium deoxycholate, and
0.1% sodium dodecyl sulfate (all Sigma)) containing Complete
protease inhibitors (Roche Applied Science). Protein concen-
tration was determined with the Dc-Protein assay (Bio-Rad) to
ensure equal gel loading. For Western blotting (36) we used
primary antibodies for Tau (Tau-5), KLC, kinesin heavy
chain (Kif5B), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), JIP1 (all Santa Cruz), JIP1 (Zymed Laboratories
Inc.), V5 andMyc (Invitrogen), Tau (DAKO), Tau phosphoryl-
ated at Ser-202/Thr-205 (AT8), at Thr-231/Ser-235 (AT180)
and at Thr-181 (AT270) (all Pierce) and at Ser-396/Ser-404
(PHF-1) (Peter Davies), and non-phosphorylated Tau (TAU1)
together with alkaline phosphatase-coupled secondary anti-
bodies (Sigma), developed with the ImmunStar substrate (Bio-
Rad) in a VersaDoc 4000 detection system (Bio-Rad). Quantifi-
cation of bands was performed with the Quantity One software
(Bio-Rad) and normalized to GAPDH expression.
Immunoprecipitation (IP) was performed as described pre-
viously (36). Briefly, tissue was lysed with a glass Dounce
homogenizer in buffer containing 20mMTris-HCl, pH 7.5, 150
mM sodium chloride, 1% Triton X-100 (Sigma) and Complete
Protease inhibitor (Roche Applied Science). After a 1-h prein-
cubationwith bovine serumalbumin (Sigma)-saturated protein
G-coupled beats (Pierce), extracts were incubated with anti-
bodies overnight at 4 °C. Antibodies were subsequently precip-
itatedwith bovine serum albumin-saturated proteinG-coupled
beads that were then washed with buffers of increasing sodium
chloride concentration (150–400 mM). The precipitate was
recovered from the beads by boiling in hot sample buffer and
separated by SDS-PAGE. IP of cultured cells were carried out in
50 mM HEPES, pH 7.5, 140 mM NaCl, 0.2% Nonidet P-40 sub-
stitute (Sigma) using protein G-coupled magnetic beads
(Invitrogen).
ExpressionVectors—JIP1, KLC, andTau encoding full-length
cDNA was amplified from a human cDNA library using Pfu
Ultra polymerase (Stratagene), cloned into TOPO gateway
entry vectors (Invitrogen), and sequenced. Subsequently, the
coding sequence was transferred into Myc, V5, or His6 expres-
sion vectors using the LR clonase reaction according to the
manual (Invitrogen).
FIGURE 1.Disturbed interaction of JIP1with the kinesin-Imotor complex
in K3 mice. A, K369I mutant human Tau expressing K3 mice (HT7) phospho-
rylate Tau atmultiple sites, includingAT8, AT180, PHF-1, andAT270, as shown
for 4-month-oldmice comparedwithwild-type (wt). Despite axonal transport
defects in K3 mice (17), protein levels of the motor proteins kinesin heavy
chain (KIF5B), KLC, and JIP1 are not altered. GAPDH served as control for equal
loading. Brain extracts from four different mice per group were analyzed.
B, although an intact JIP1KLCKIF5B complex could be immunoprecipitated
from wild-type mouse brain extracts with either an antibody against JIP1,
KLC, or KIF5B, in K3 brain only the KLC/KIF5B interaction could be revealed,
with no JIP1 in the complex. Representative blots from at least three inde-
pendent experiments are shown. C, IP of Tau from K3 and wild-type brain
extracts reveals a Tau/JIP1 interaction in K3 and notwild-type brain. Similarly,
IP with a JIP1 antibody co-precipitates Tau from K3 but not wild-type mouse
brain. Representative blots from three experiments are shown.
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Pulldown Experiments—Pulldown experiments were carried
out with His6-tagged recombinant proteins using the TALON
metal affinity resin (Clontech) following the manufacturer’s
instructions. Briefly, carboxyl-terminal His6-V5-tagged pro-
teins were expressed in BL21-AI E. coli and purified after lysis
by sonication in immunoprecipitation buffer. Tau was phos-
phorylated in vitro as described previously (37). Subsequently,
the resin-bound proteins were incubated with extracts from
wild-type mouse brains overnight at 4 °C. The columns were
then washed with buffers of increasing sodium chloride con-
centration (150–400 mM). The precipitate was recovered from
the resin by boiling hot sample buffer and separated by
SDS-PAGE.
Cell Culture and Immunofluorescence—All cell culture
media and reagents were supplied by Invitrogen unless stated
otherwise. COS7 cellsmaintained in
Dulbecco’s modified Eagle’s medi-
um/F-12 containing 10% fetal
bovine serum (Hyclone) and trans-
fected as previously described (36).
Cells were incubated with okadaic
acid (OA) in culture medium for
10 h at 37 °C, 5%CO2.
Primary hippocampal neurons
were cultured following an estab-
lished protocol (38, 39). Primary
hippocampal neurons were trans-
fected by calcium/DNA precipita-
tion as described before (40).
For immunofluorescence stain-
ing, coverslips were removed after 7
days and fixed with 4% paraformal-
dehyde in 80 mM PIPES, 1 mM
MgCl2, and 1 mM EGTA, pH 6.8.
Cells were permeabilized with 0.1%
Triton in phosphate-buffered saline
and stained with antibodies to V5
and JIP1.
Quantification of Immunofluores-
cence Staining—Immunofluores-
cence intensity was measured on
images takenwith an IX81-Xmicro-
scope (Olympus, Japan). Images
were background-subtracted and
analyzed for fluorescence intensity
using the MetaMorph 6.1 software
(Molecular Devices).
Statistics—Statistical analysis was
done with the Prizm 4 forWindows
software (GraphPad Software)
using Student’s t test. All values are
given as the means S.E.
RESULTS
Disturbed Interaction of JIP1 with
Kinesin-I Motor Complexes in K3
Mice—Tau overexpression in vitro
(41) and in wild-type human Tau
(16, 42, 43) and K369I mutant Tau transgenic K3 mice (17)
results in axonal transport defects. In cell culture and, in par-
ticular, in K3 brains, transport of distinct kinesin-driven cargos
is impaired in the presence of transgenic Tau, whereas trans-
port of other cargos remains unaffected (17, 19, 41). These
observations raised the question of whether Tau would inter-
fere with components of the axonal transport machinery
directly. Several of the cargos whose transport is affected by
Tau expression are driven by the kinesin-Imotor complex. This
complex is formed by the kinesin heavy chain (KIF5; previously
termed KHC), which interacts with microtubules, and kinesin
light chain (KLC), which mediates cargo linkage. In addition,
scaffolding proteins are involved such as the JIP1 that binds to
KLC (21). Hence, we questioned whether transgenic Tau
expression in K3 mice would interfere with the integrity of the
FIGURE 2. Tau-dependent re-distribution of JIP1 in K3 neurons. A, immunohistochemistry of sagittal brain
sections reveals a predominantly axonal staining of JIP1 (green) in wild-type mice, with little staining of neu-
ronal cell bodies. In contrast, JIP1 accumulates in the cell body of cortical neurons of K3 mice, whereas axons
hardly contain JIP1. Neurons were counter-stained with microtubule-associated protein 2 (MAP2) or neuronal
nuclei (NeuN) (red). Scale bar, 100m. B, highermagnification (boxes in A) of layer V neuronal cell bodies (soma
(s)) and their axons (a) passing through neuronal layer VI. JIP1 accumulates in K3 neuronal cell bodies (arrow-
head), whereas they are hardly stainable in wild-type (wt) neurons. C, thus, the ratio of somatic versus axonal
JIP1 is significantly increased in K3 mice, indicating trapping of JIP1 in the cell body (*, p 0.0001).
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kinesin-I complex and thereby cause impaired axonal transport
(17).
To address this, we performed a series of co-immunoprecipi-
tation experiments from K3 compared with wild-type control
brain extracts using antibodies to KIF5B, KLC, and JIP1. Trans-
genic expression of K369I mutant human Tau resulted in
increased levels of phosphorylated Tau, as revealed byWestern
blot analysis of wild-type and K3 brain extracts (Fig. 1A). Pro-
tein levels of KIF5B, KLC, and JIP1, however, were comparable
in wild-type and K3 mice (Fig. 1A). Intact kinesin-I complexes
were present in wild-type brain extracts, as revealed by co-im-
munoprecipitation of KIF5B and JIP1 with an antibody to KLC,
of KLC and JIP1 with an antibody to KIF5B, and of KIF5B and
KLCwith an antibody to JIP1 (Fig. 1B). Similarly, fromK3 brain
extracts, KLC co-immunoprecipitated together with KIF5B
using antibodies to KLC and KIF5B, respectively. Interestingly,
and different from wild-type brain, hardly any JIP1 co-immu-
noprecipitated from K3 brain extracts using either antibodies
to KLC or KIF5B, and neither KLC nor KIF5B co-immunopre-
cipitated when an antibody to JIP1 was used. Taken together,
KIF5BKLCJIP1 complexes exist in wild-type brain, whereas
in K3 brain, JIP1 appears to be excluded from KIF5BKLC
complexes.
Tau/JIP1 Interaction inK3Mice—The exclusion of JIP1 from
KIF5BKLC complexes in K3 brain raised the question of
whether a reduced kinesin/JIP1 interaction would be a second-
ary effect of transgenic Tau expression or whether Tau would
directly interfere with complex formation. To address the latter
possibility, we performed additional co-immunoprecipitation
experiments with antibodies to JIP1 and total Tau using wild-
type and K3 brain extracts. Neither did JIP1 co-immunopre-
cipitate with an antibody to Tau, nor did Tau co-precipitate
with an antibody to JIP1 usingwild-type brain extracts (Fig. 1C).
However, using the same experimental conditions, JIP1 co-im-
munoprecipitated from K3 brain extracts using an antibody to
Tau. As a substantial amount of JIP1 was co-immunoprecipi-
tated, this suggests a strong Tau/Jip-1 interaction. Thus, the
lack of kinesin/JIP1 interaction occurs together with an aber-
rant Tau/JIP1 interaction in K3 brains.
Altered Sequestration of JIP1 in K3 and AD Brains—As the
reduced interaction of JIP1 with kinesin motors may alter the
subcellular localization of JIP1, we compared its distribution on
brain sections of K3 and wild-typemice by immunohistochem-
istry (Fig. 2A). In wild-type cortex, JIP1 immunohistochemistry
revealed a pre-dominantly axonal staining. In contrast, cortical
K3 neurons showed a pronounced staining of cell bodies
(soma), whereas their axons hardly stained, as revealed by co-
immunofluorescence staining for JIP1 and the neuronal mark-
ers microtubule-associated protein 2 and neuronal nuclei.
Quantification revealed a 3.2-fold increased soma:axon ratio
for JIP1 in K3 compared with wild-type cortex (Fig. 2, B andC).
Thus, JIP1 is retained in cell bodies of cortical K3 neurons.
In AD, Tau is known to become hyperphosphorylated and
redistributed from the axon to the somato-dendritic compart-
ment. We questioned whether Tau redistribution in AD brain
would also be associated with a somatic retention of JIP1, as has
been observed by us in K3 mice. Therefore, we quantified JIP1
staining of AD and control human brain sections, as we had
done formice.We found that in temporal cortex of AD, and not
control brain, neuronal cell bodies showed a pronounced JIP1
staining (Fig. 3A), whereas reactivity in the axons of the white
matter within the same brain area was markedly reduced,
resulting in an increased gray matter to white matter ratio of
JIP1 in AD compared with controls (Fig. 3B).
Next, we addressedTau-JIP1 complex formation inADcom-
paredwith human control brains. As done before for themouse
brains, we performed co-immunoprecipitation experiments
with antibodies to JIP1 and Tau using cortical AD and control
brain extracts. Both precipitations revealed the presence of
Tau-JIP1 complexes in AD, but not control, brain (Fig. 3C). In
addition, we found that JIP1 co-localized with phosphorylated
Tau in NFTs using JIP1/AT180 co-immunofluorescence stain-
ing with subsequent visualization of NFTs by Gallyas silver
impregnations (Fig. 3D). Taken together, we have shown that,
first, Tau interacts with JIP1 in AD brain and, second, that JIP1
is retained in the soma of AD neurons.
Sequestration of JIP in Tau-expressing Primary Neurons—K3
mice express mutant Tau, whereas in AD Tau is not mutated.
To address the role of the K369I mutation of Tau in the
FIGURE 3. Pathological re-distribution of JIP1 in AD brain. A, lowmagnifi-
cation images of JIP1-stained (brown) sections from the temporal cortex of
control (CO) brains show a low signal in gray matter (gm) (inset at higher
magnification) and intensive staining of axons in the white matter (wm). In
contrast, the white matter of AD tissue sections stains less for JIP1, whereas
gray matter neurons (inset) show intensive JIP1 staining. Scale bar, 250 m.
B, quantification reveals a re-distributionof JIP1 from the axon to the soma, as
shown by an increased ratio of somatic versus axonal staining (*, p 0.0001).
C, JIP1 co-immunoprecipitates with Tau from human AD but not control (CO)
brain extracts. Similarly, IP using a JIP1 antibody co-precipitates Tau from AD
but not CO brains. Representative blots from three experiments are shown.
D, JIP1 (red)/AT180 (green) co-immunofluorescence staining shows co-local-
ization (merge) in NFTs, which stain with Gallyas silver.
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trapping of JIP1 in the neuronal soma, we transfected pri-
mary neuronal cultures with different expression constructs.
We found that in mock-transfected hippocampal neurons,
endogenous JIP1 showed an axonal distribution with an
increased accumulation toward the axonal growth cones, as
is typical for axon-transported proteins (Fig. 4A). We spec-
ulated that upon Tau transfection,
the kinesin/JIP1 interaction would
be disrupted, causing JIP1 to accu-
mulate in the cell body and, hence,
to be reduced in the growth cones.
When we co-transfected primary
hippocampal neurons with a green
fluorescent protein marker for
axonal tracing together with Tau,
both in the presence and absence
of the K369I mutation, JIP1 stain-
ing was decreased in the growth
cone and accumulated in the cell
body. Also, when we co-trans-
fected Tau together with JIP1, this
resulted in somatic retention of
JIP1 (Fig. 4, B and C). Taken
together, our data show that
expression of Tau, irrespective of
the presence of the K369I muta-
tion, induces a redistribution and
trapping of JIP1 in the cell body
and, hence, a reduced localization
to axons and the growth cone.
Hyperphosphorylation of Tau Is
Needed for the Pathological Inter-
action of Tau with JIP1—As we
had identified Tau-JIP1 complexes
in both K3 and AD but not wild-
type murine and control human
brains, we speculated that patho-
logical changes in Tau, such as
hyperphosphorylation, are needed
for the pathological interaction of
Tau with JIP1. This notion is sup-
ported by our finding that recom-
binant bacterial humanTau,which
is not phosphorylated, fails to pull
down JIP1 from mouse brain
extracts (data not shown). Only
when recombinant Tau obtained
from Escherichia coli was phos-
phorylated in vitro, it pulled down
substantial amounts of JIP1 from
brain extracts, providing for the
first time experimental evidence
that phosphorylation of Tau is
required for its pathological inter-
action with JIP1 (Fig. 5A).
Therefore, we performed co-im
munoprecipitation experiments
from transiently transfected COS7
cells. First, we expressed Myc-tagged JIP1 together with
either V5-tagged Tau or KLC followed by immunoprecipita-
tion with an anti-Myc antibody. As expected, KLC, but not
Tau co-immunoprecipitated with JIP1 (Fig. 5B), as Tau in
transfected COS7 cells is hardly at all phosphorylated (Fig. 5C).
However, treatment of cells with the protein phosphatase
FIGURE 4. Impaired axonal distribution of JIP1 is not caused by the K369I mutation of Tau. A, to
determine whether the impaired axonal localization of JIP1 is due to the presence of K369I mutant Tau
rather than elevated levels of hyperphosphorylated Tau per se, primary hippocampal neurons were trans-
fected with MOCK, V5-wt-Tau, or V5-K369I mutant Tau together with green fluorescent protein (GFP) to
visualize axonal tracing. In MOCK co-transfected neurons, JIP1 undergoes axonal transport and accumu-
lates in growth cones (arrowheads; inset). In contrast, neurons co-transfected with V5-Tau (yellow merge)
fail to accumulate JIP1 in growth cones (open arrowheads; inset). Note the intense JIP1 staining of the
growth cone in untransfected neurons (arrowhead). Co-transfection of V5-K369I mutant Tau also results in
a decreased JIP1 staining of growth cones. Scale bar, 50 m. wt, wild type. B, co-transfection of primary
hippocampal neurons with either V5-wt-Tau or V5-K369I mutant Tau together with Myc-JIP1 results in
intensive JIP1 staining of the cell body (arrowheads), that is not found when the neurons are only trans-
fected with the Myc-JIP1 construct (open arrowhead). Inset, staining for Tau. Scale bar, 50 m. C, when
staining is quantified, Myc-JIP1 fluorescence intensity shows increased levels of JIP1 in neurons that
co-express either V5-wt-Tau or V5-K369I mutant Tau compared with co-transfection with an empty plas-
mid (MOCK; *, p 0.0001). Thus, an increase of Tau in the cell body of neurons results in retention of JIP1,
along with a decreased axonal distribution.
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inhibitor OA caused a dose-dependent hyperphosphorylation
of Tau at multiple sites, including AT8, AT180, AT270, and
PHF-1, without changing total Tau levels (Fig. 5C) (44). There-
fore, we next performed a co-immunoprecipitation with an
anti-Myc antibody from extracts of COS7 cells that had been
transfected with Myc-tagged JIP1 and V5-tagged Tau and
treated with increasing doses of OA. Supporting the notion
that the Tau/JIP1 interaction depends on hyperphosphoryl-
ation of Tau, increasing amounts of Tau co-immunoprecipi-
tated with JIP1 when increasing doses of OA were used (Fig.
5D). Thus, phosphorylation of Tau is needed for the interac-
tion of Tau with JIP1.
Finally, we determined whether
Tau can compete with KLC for the
interaction with JIP1. Co-immu-
noprecipitation with an antibody
to Myc from COS7 cells co-trans-
fected with Myc-tagged JIP1 and
V5-tagged KLC and Tau revealed
co-precipitation of KLCJIP1 but
not Tau-JIP1 complexes (Fig. 5E,
lane 1). OA treatment of cells that
had been co-transfected with
Myc-tagged JIP1 and V5-tagged
KLC reduced the amount of
co-immunoprecipitated KLCJIP1
complexes (Fig. 5E, lane 2). How-
ever, co-expression of Tau to-
gether with Myc-tagged JIP1 and
V5-tagged KLC resulted in a
marked 85% reduction of co-im-
munoprecipitated KLCJIP1 com-
plexes upon OA treatment (Fig.
5E, lane 3). As expected, JIP1 co-
precipitated Tau under these con-
ditions. Taken together, our data
reveal that hyperphosphorylated
Tau competes with KLC for the
interaction with JIP1.
DISCUSSION
In the present study, which
combines the analysis of trans-
genic brain, human brain samples,
primary cultures, and in vitro
experiments, we found that hyper-
phosphorylated Tau disrupts the
functional binding of JIP1 to the
kinesin-I motor complex. We
found that Tau pathologically
interacts with JIP1 both in our K3
mouse model and in AD brain,
causing a re-localization of JIP1
from axons to cell bodies. When
Tau was expressed in primary hip-
pocampal neurons, this also
resulted in a decreased axonal
localization concomitant with an
accumulation of JIP1 in cell bodies. Finally, we showed that
the Tau/JIP1 interaction is phosphorylation-dependent and
that this pathologic interaction competes with the binding of
JIP1 to KLC.
Regulation of axonal transport remains poorly under-
stood, but it has been suggested recently that it may be reg-
ulated at the level of cargo binding to the motors (21, 26). Of
the proteins involved in cargo binding, JIP1 has been found
to interact specifically with KLC (29, 45). JIP is also a scaf-
folding protein for different components of the JNK signal-
ing cascade, including JNK and its upstream kinases (46–
48). JNK activation has been shown to regulate the kinesin/
FIGURE 5.Hyperphosphorylation of Tau is required for Tau to compete with KLC in the interaction with
JIP1. A, recombinant hyperphosphorylated Tau carrying a carboxyl-terminal V5 and six-histidine tag (P-Tau-
6His)wasusedasbait to identify interactionpartners of the kinesin-I-JIP complex fromwild-typemousebrain
extracts (load). JIP1 (asterisk) was pulled downwith P-Tau-His6. Neither JIP2, JIP3, KLC, nor kinesin heavy chain
(KIF5B) co-precipitatedwith P-Tau-His6. Recombinant Tauwas visualizedwithV5 andTau-5 antibodies.B, COS7
cellswere co-transfectedwithMyc-JIP1 andV5-Tau (lane 1) or V5-KLC (lane 2). Immunoprecipitationwith aMyc
antibody precipitates JIP1 and co-precipitates V5-KLC but not V5-Tau. GAPDH served as loading control.
C, treatment of COS7 cells that have been co-transfected with Myc-JIP1 and V5-Tau with increasing concen-
trations of the protein phosphatase inhibitor OA causes increased phosphorylation of Tau at multiple sites
including AT8, AT180, PHF-1, and AT270. OA treatment did not affect Tau levels, as revealed by Tau-1. GAPDH
served as control for equal loading.D, co-immunoprecipitation fromOA-treated transfected cells (d) results in
a dose-dependent increase of V5-Tau co-precipitated with Myc-JIP1. E, COS7 cells transfected with Myc-JIP1
andV5-KLCwith (lanes 1and3) andwithoutV5-Tau (lane2) treatedwith20nMOA.OA impedes co-precipitation
of V5-KLC with Myc-JIP1, most significantly in the presence of V5-Tau that then co-precipitates with Myc-JIP1.
Quantification is shown for three independent experiments normalized for levels in the absence of OA (lane
1; *, p 0.001).
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cargo binding by mediating the release of cargos once they
have reached their final destination in the distal axon (26).
Axonal transport defects in spinal and bulbar muscle atro-
phy have been suggested to result from increased JNK activ-
ity and subsequent phosphorylation of kinesin (27).
Impaired anterograde axonal transport has also been
implicated in the pathogenesis of diseases such as AD (8).
Many of these disorders are associated with Tau pathology.
Thus, the aberrant interaction we have identified for phos-
phorylated Tau and the scaffold protein JIP1, whether direct
or indirect, may explain, at least in part, impaired axonal
transport. Mechanistically, we propose that the Tau/JIP1
interaction competes with the physiological binding of JIP1
to KLC. Hence, JIP1 fails in scaffolding regulatory kinases to
the kinesin-I motor complex in axons. As a consequence,
anterograde axonal transport of cargos specifically trans-
ported by the kinesin-I complex is impaired, eventually dis-
turbing normal neuronal function. This pathomechanism
may explain the clinical symptoms of Tau transgenic mice
(17) and, possibly, neuronal dysfunction in AD and FTD.
Our in vivo finding that JIP1 fails to interact with KLC and
is instead bound by phosphorylated Tau and retained in the
cell body is consistent with an increased JIP1 staining in the
soma of neurons in both K3 mice and in AD (49). Because
JIP1 is also a scaffolding protein for several kinases, many of
which phosphorylate Tau, it cannot be excluded that JIP1
mislocalization may also promote hyperphosphorylation of
Tau in the soma, establishing a vicious cycle.
Although we cannot rule out that the Tau/JIP1 interaction
may also have a physiological function in axonal transport, our
data indicate that breaking up the aberrant Tau/JIP1 interac-
tion may restore anterograde axonal transport and, hence, rep-
resent a novel approach in treating neurodegenerative diseases
with Tau pathology.
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